Indications
Therapeutic Asset Ratings
6,305 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Quemliclustat
Ureter Transitional Cell Carcinoma
Fred Hutchinson Cancer Center
P1/2
CC
(47)
Quemliclustat
Infiltrating Bladder Urothelial Carcinoma
Fred Hutchinson Cancer Center
P1/2
CC
(47)
Quemliclustat
Malignant Renal Pelvis Neoplasm
Fred Hutchinson Cancer Center
P1/2
CC
(47)
Quemliclustat
Ureter Cancer
Fred Hutchinson Cancer Center
P1/2
CC
(47)
Recombinant Human Egf-Rp64K
Non-Small Cell Squamous Lung Carcinoma
Roswell Park Cancer Institute
P1/2
CC
(47)
Recombinant Human Granulocyte Colony-Stimulating Factor
Acute Biphenotypic Leukemia
University of Washington
P1/2
CC
(47)
Recombinant Human Granulocyte Colony-Stimulating Factor
Hematopoietic And Lymphoid Cell Neoplasm
Fred Hutchinson Cancer Center
P1/2
CC
(47)
Recombinant Human Granulocyte Colony-Stimulating Factor
Myelodysplastic Syndrome With Excess Blasts
Fred Hutchinson Cancer Center
P1/2
CC
(47)
Regn15505
Nonpapillary Renal Cell Carcinoma
Regeneron Pharmaceuticals
P1/2
CC
(47)
Regn4336
Nonpapillary Renal Cell Carcinoma
Regeneron Pharmaceuticals
P1/2
CC
(47)
Regv131
Hemophilia B
Regeneron Pharmaceuticals
P1/2
CC
(47)
Relatlimab
Hodgkins Lymphoma
Bristol-Myers Squibb
P1/2
CC
(47)
Retifanlimab
Astrocytoma, IDH-Mutant, Grade 4
Mayo Clinic
P1/2
CC
(47)
Retifanlimab
High Grade B-Cell Lymphoma
University of Washington
P1/2
CC
(47)
Rezatapopt
Gallbladder Cancer
PMV Pharmaceuticals, Inc
P1/2
CC
(47)
Ribociclib
Invasive Breast Carcinoma
Jonsson Comprehensive Cancer Center
P1/2
CC
(47)
Rifaximin
Cervical Adenocarcinoma
Mansoura University
P1/2
CC
(47)
Rimiducid
Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
P1/2
CC
(47)
Rintatolimod
Malignant Pancreatic Neoplasm
Joachim Aerts, MD PhD
P1/2
CC
(47)
RM-718
Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc.
P1/2
CC
(47)
RM-718
Prader-Willi Syndrome
Rhythm Pharmaceuticals, Inc.
P1/2
CC
(47)
rn3161
Obesity Disorder
Ikaria Bioscience Pty Ltd
P1/2
CC
(47)
RNK05047
Diffuse Large B-Cell Lymphoma
Ranok Therapeutics (Hangzhou) Co., Ltd.
P1/2
CC
(47)
Rocbrutinib
Follicular Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
P1/2
CC
(47)
rp-001
Cancer
Recurv Pharma Inc
P1/2
CC
(47)
Showing 2576 to 2600 of 6,305 assets
Previous
Page 104 of 253
Next